June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

Please provide your email address to receive an email when new articles are posted on . According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual ...

At the American Academy of Ophthalmology (AAO) annual meeting, new data were presented from a 7-month analysis on OTX-TKI, an axitinib (Inlyta) intravitreal implant being evaluated for the treatment ...

Preplanned subgroup analysis of the MEAD study results showed that DEX implant 0.7 mg significantly improved visual and anatomic outcomes in patients with a history of previous medical or laser ...

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin. Patients who have diabetic macular edema ...

brolucizumab-dbll Beovu 6mg/0.05mL soln for intravitreal inj 6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks. ranibizumab Lucentis 6mg/mL ...

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...